1
|
Wu Q, Qin SK, Teng FM, Chen CJ and Wang R:
Lobaplatin arrests cell cycle progression in human hepatocellular
carcinoma cells. J Hematol Oncol. 3:432010. View Article : Google Scholar : PubMed/NCBI
|
2
|
Zaanan A, Williet N, Hebbar M, Dabakuyo
TS, Fartoux L, Mansourbakht T, Dubreuil O, Rosmorduc O, Cattan S,
Bonnetain F, et al: Gemcitabine plus oxaliplatin in advanced
hepatocellular carcinoma: A large multicenter AGEO study. J
Hepatol. 58:81–88. 2013. View Article : Google Scholar
|
3
|
Qin S, Bai Y, Lim HY, Thongprasert S, Chao
Y, Fan J, Yang TS, Bhudhisawasdi V, Kang WK, Zhou Y, et al:
Randomized, multicenter, open-label study of oxaliplatin plus
fluorouracil/leucovorin versus doxorubicin as palliative
chemotherapy in patients with advanced hepatocellular carcinoma
from Asia. J Clin Oncol. 31:3501–3508. 2013. View Article : Google Scholar : PubMed/NCBI
|
4
|
Petrelli F, Coinu A, Borgonovo K, Cabiddu
M, Ghilardi M, Lonati V and Barni S: Oxaliplatin-based
chemotherapy: A new option in advanced hepatocellular carcinoma. a
systematic review and pooled analysis. Clin Oncol (R Coll Radiol).
26:488–496. 2014. View Article : Google Scholar
|
5
|
Abdel-Rahman O: Revisiting
oxaliplatin-based regimens for advanced hepatocellular carcinoma.
Curr Oncol Rep. 16:3942014. View Article : Google Scholar : PubMed/NCBI
|
6
|
Miao J, Chen GG, Chun SY, Chak EC and Lai
PB: Bid sensitizes apoptosis induced by chemotherapeutic drugs in
hepatocellular carcinoma. Int J Oncol. 25:651–659. 2004.PubMed/NCBI
|
7
|
Vinken M, Vanhaecke T, Papeleu P, Snykers
S, Henkens T and Rogiers V: Connexins and their channels in cell
growth and cell death. Cell Signal. 18:592–600. 2006. View Article : Google Scholar
|
8
|
Brockmeyer P, Jung K, Perske C,
Schliephake H and Hemmerlein B: Membrane connexin 43 acts as an
independent prognostic marker in oral squamous cell carcinoma. Int
J Oncol. 45:273–281. 2014.PubMed/NCBI
|
9
|
Krutovskikh VA, Piccoli C and Yamasaki H:
Gap junction inter-cellular communication propagates cell death in
cancerous cells. Oncogene. 21:1989–1999. 2002. View Article : Google Scholar : PubMed/NCBI
|
10
|
Jensen R and Glazer PM:
Cell-interdependent cisplatin killing by Ku/DNA-dependent protein
kinase signaling transduced through gap junctions. Proc Natl Acad
Sci USA. 101:6134–6139. 2004. View Article : Google Scholar : PubMed/NCBI
|
11
|
Tanaka M and Grossman HB: Connexin 26 gene
therapy of human bladder cancer: Induction of growth suppression,
apoptosis, and synergy with Cisplatin. Hum Gene Ther. 12:2225–2236.
2001. View Article : Google Scholar
|
12
|
Shishido SN and Nguyen TA: Gap junction
enhancer increases efficacy of cisplatin to attenuate mammary tumor
growth. PLoS One. 7:e449632012. View Article : Google Scholar : PubMed/NCBI
|
13
|
Yoon SY, Robinson CR, Zhang H and
Dougherty PM: Spinal astrocyte gap junctions contribute to
oxaliplatin-induced mechanical hypersensitivity. J Pain.
14:205–214. 2013. View Article : Google Scholar : PubMed/NCBI
|
14
|
Bai C, Yang M, Fan Z, Li S, Gao T and Fang
Z: Associations of chemo- and radio-resistant phenotypes with the
gap junction, adhesion and extracellular matrix in a
three-dimensional culture model of soft sarcoma. J Exp Clin Cancer
Res. 34:582015. View Article : Google Scholar : PubMed/NCBI
|
15
|
Mesnil M: Connexins and cancer. Biol Cell.
94:493–500. 2002. View Article : Google Scholar
|
16
|
Cronier L, Crespin S, Strale PO, Defamie N
and Mesnil M: Gap junctions and cancer: New functions for an old
story. Antioxid Redox Signal. 11:323–338. 2009. View Article : Google Scholar
|
17
|
Vinken M, De Kock J, Oliveira AG, Menezes
GB, Cogliati B, Dagli ML, Vanhaecke T and Rogiers V: Modifications
in connexin expression in liver development and cancer. Cell Commun
Adhes. 19:55–62. 2012. View Article : Google Scholar : PubMed/NCBI
|
18
|
Zhang JT and Nicholson BJ: The topological
structure of connexin 26 and its distribution compared to connexin
32 in hepatic gap junctions. J Membr Biol. 139:15–29. 1994.
View Article : Google Scholar : PubMed/NCBI
|
19
|
Maes M, Decrock E, Cogliati B, Oliveira
AG, Marques PE, Dagli ML, Menezes GB, Mennecier G, Leybaert L,
Vanhaecke T, et al: Connexin and pannexin (hemi)channels in the
liver. Front Physiol. 4:4052014. View Article : Google Scholar : PubMed/NCBI
|
20
|
Plante I, Charbonneau M and Cyr DG:
Decreased gap junctional intercellular communication in
hexachlorobenzene-induced gender-specific hepatic tumor formation
in the rat. Carcinogenesis. 23:1243–1249. 2002. View Article : Google Scholar : PubMed/NCBI
|
21
|
Ma XD, Sui YF and Wang WL: Expression of
gap junction genes connexin 32, connexin 43 and their proteins in
hepatocellular carcinoma and normal liver tissues. World J
Gastroenterol. 6:66–69. 2000. View Article : Google Scholar
|
22
|
Nakashima Y, Ono T, Yamanoi A, El-Assal
ON, Kohno H and Nagasue N: Expression of gap junction protein
connexin32 in chronic hepatitis, liver cirrhosis, and
hepatocellular carcinoma. J Gastroenterol. 39:763–768. 2004.
View Article : Google Scholar : PubMed/NCBI
|
23
|
Bevans CG, Kordel M, Rhee SK and Harris
AL: Isoform composition of connexin channels determines selectivity
among second messengers and uncharged molecules. J Biol Chem.
273:2808–2816. 1998. View Article : Google Scholar : PubMed/NCBI
|
24
|
Ayad WA, Locke D, Koreen IV and Harris AL:
Heteromeric, but not homomeric, connexin channels are selectively
permeable to inositol phosphates. J Biol Chem. 281:16727–16739.
2006. View Article : Google Scholar : PubMed/NCBI
|
25
|
Zheng R, Wang J, Wu Q, Wang Z, Ou Y, Ma L,
Wang M, Wang J and Yang Y: Expression of ALDH1 and TGFβ2 in benign
and malignant breast tumors and their prognostic implications. Int
J Clin Exp Pathol. 7:4173–4183. 2014.
|
26
|
He XD, Wang Y, Wu Q, Wang HX, Chen ZD,
Zheng RS, Wang ZS, Wang JB and Yang Y: Xuebijing protects rats from
sepsis challenged with acinetobacter baumannii by promoting Annexin
A1 expression and inhibiting proinflammatory cytokines secretion.
Evid Based Complement Alternat Med. 2013:8049402013. View Article : Google Scholar : PubMed/NCBI
|
27
|
Yang Y, Qin SK, Wu Q, Wang ZS, Zheng RS,
Tong XH, Liu H, Tao L and He XD: Connexin-dependent gap junction
enhancement is involved in the synergistic effect of sorafenib and
all-trans retinoic acid on HCC growth inhibition. Oncol Rep.
31:540–550. 2014.
|
28
|
Yang Y, Cao MH, Wang Q, Yuan DD, Li L and
Tao L: The effects of 2-aminoethoxydiphenyl borate and
diphenylboronic anhydride on gap junctions composed of Connexin43
in TM(4) sertoli cells. Biol Pharm Bull. 34:1390–1397. 2011.
View Article : Google Scholar
|
29
|
Eugenín EA, Eckardt D, Theis M, Willecke
K, Bennett MV and Saez JC: Microglia at brain stab wounds express
connexin 43 and in vitro form functional gap junctions after
treatment with interferon-gamma and tumor necrosis factor-alpha.
Proc Natl Acad Sci USA. 98:4190–4195. 2001. View Article : Google Scholar : PubMed/NCBI
|
30
|
Garg S, Md Syed M and Kielian T:
Staphylococcus aureus-derived peptidoglycan induces Cx43 expression
and functional gap junction intercellular communication in
microglia. J Neurochem. 95:475–483. 2005. View Article : Google Scholar : PubMed/NCBI
|
31
|
Sáez CG, Velásquez L, Montoya M, Eugenín E
and Alvarez MG: Increased gap junctional intercellular
communication is directly related to the anti-tumor effect of
all-trans-retinoic acid plus tamoxifen in a human mammary cancer
cell line. J Cell Biochem. 89:450–461. 2003. View Article : Google Scholar : PubMed/NCBI
|
32
|
Wang J, Dai Y, Huang Y, Chen X, Wang H,
Hong Y, Xia J and Cheng B: All-trans retinoic acid restores gap
junctional intercellular communication between oral cancer cells
with upregulation of Cx32 and Cx43 expressions in vitro. Med Oral
Patol Oral Cir Bucal. 18:e569–e577. 2013. View Article : Google Scholar : PubMed/NCBI
|
33
|
Mesnil M, Crespin S, Avanzo JL and
Zaidan-Dagli ML: Defective gap junctional intercellular
communication in the carcinogenic process. Biochim Biophys Acta.
1719:125–145. 2005. View Article : Google Scholar : PubMed/NCBI
|
34
|
Leithe E, Sirnes S, Omori Y and Rivedal E:
Downregulation of gap junctions in cancer cells. Crit Rev Oncog.
12:225–256. 2006. View Article : Google Scholar
|
35
|
Dejana E, Orsenigo F, Molendini C, Baluk P
and McDonald DM: Organization and signaling of endothelial
cell-to-cell junctions in various regions of the blood and
lymphatic vascular trees. Cell Tissue Res. 335:17–25. 2009.
View Article : Google Scholar
|
36
|
Lampugnani MG and Dejana E: The control of
endothelial cell functions by adherens junctions. Novartis Found
Symp. 283:4–13; discussion 13–17, 238–241. 2007. View Article : Google Scholar
|
37
|
Yano T, Hernandez-Blazquez FJ, Omori Y and
Yamasaki H: Reduction of malignant phenotype of HEPG2 cell is
associated with the expression of connexin 26 but not connexin 32.
Carcinogenesis. 22:1593–1600. 2001. View Article : Google Scholar : PubMed/NCBI
|
38
|
Yamasaki H and Naus CC: Role of connexin
genes in growth control. Carcinogenesis. 17:1199–1213. 1996.
View Article : Google Scholar : PubMed/NCBI
|
39
|
Wang Z, Zhou J, Fan J, Qiu SJ, Yu Y, Huang
XW, Sun J, Tan CJ and Dai Z: Oxaliplatin induces apoptosis in
hepatocellular carcinoma cells and inhibits tumor growth. Expert
Opin Investig Drugs. 18:1595–1604. 2009. View Article : Google Scholar : PubMed/NCBI
|
40
|
Gao J, Wang R, Yang Q, Chen C and Wu Q:
Effect of Oxaliplatin on cell cycle of hepatocellular carcinoma
cell line HepG2. Zhejiang Da Xue Xue Bao Yi Xue Ban. 42:437–442.
2013.(In Chinese). PubMed/NCBI
|